Huh et al. HCQ for COVID-19 PrEP
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea
et al., International Journal of Infectious Diseases,
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South..
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041
Retrospective database analysis with 17 cases for existing HCQ users and 5 severe cases, showing no significant difference for cases and higher risk for severe cases. However, HCQ users are likely systemic autoimmune disease patients and authors do not adjust for the very different baseline risk for these patients. Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42,
This study is excluded in the after exclusion results of meta
not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of progression, , treatment 5 of 8 (62.5%), control 873 of 2,797 (31.2%), adjusted per study, multivariate.
251.0% higher, RR 3.51, p = 0.11
risk of case, , treatment 17 of 122 (13.9%), control 7,324 of 43,924 (16.7%), adjusted per study, multivariate.
6.0% lower, RR 0.94, p = 0.82
Effect extraction follows
pre-specified rules prioritizing more serious outcomes. Submit updates
Huh et al., 19 Dec 2020, retrospective, database analysis, South Korea, peer-reviewed, 8 authors.
Abstract: International Journal of Infectious Diseases 104 (2021) 7–14
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier.com/locate/ijid
Association of prescribed medications with the risk of COVID-19
infection and severity among adults in South Korea
Kyungmin Huha,1, Wonjun Jib,1, Minsun Kangc,1, Jinwook Hongc, Gi Hwan Baec ,
Rugyeom Leec , Yewon Nac, Jaehun Jungc,d,*
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, South Korea
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea
Artiﬁcial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, 21565, South Korea
Department of Preventive Medicine, Gachon University College of Medicine, Incheon, 21565, South Korea
A R T I C L E I N F O
A B S T R A C T
Received 16 September 2020
Received in revised form 15 December 2020
Accepted 15 December 2020
Objectives: Concerns have been expressed that some drugs may increase susceptibility to SARS-CoV-2
infection. In contrast, other drugs have generated interest as potential therapeutic agents.
Methods: All adults aged 18 years who were tested for COVID-19 were included. Exposure was deﬁned
as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19
or later. The outcome measures were the diagnosis of COVID-19 and severe COVID-19. Disease risk score
matching and multiple logistic regression was used.
Results: Matched claims and testing results were available for 219,961 subjects, of whom 7,341 (3.34%)
were diagnosed with COVID-19. Patients were matched to 36,705 controls, and the subset of 878 patients
of severe COVID-19 also matched with 1,927 mild-to-moderate patients. Angiotensin receptor blockers
were not associated with either the diagnosis of COVID-19 (adjusted OR [aOR], 1.02; 95% conﬁdence
interval [CI], 0.90–1.15) or severe disease (aOR, 1.11; 95% CI, 0.87–1.42). The use of hydroxychloroquine
was not associated with a lower risk for COVID-19 (aOR, 0.94; 95% CI, 0.53–1.66) or severe disease (aOR,
3.51; 95% CI, 0.76–16.22).
Conclusions: In this national claims data-based case-control study, no commonly prescribed medications
were associated with risk of COVID-19 infection or COVID-19 severity.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
Disease risk score
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
provide treatment protocols.